Neil Josephson - 10 Nov 2021 Form 4 Insider Report for Zymeworks Inc.

Role
Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
10 Nov 2021
Net transactions value
$0
Form type
4
Filing time
12 Nov 2021, 20:00:27 UTC
Previous filing
08 Jul 2021
Next filing
11 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +105,943 $0.000000 105,943 10 Nov 2021 Common Shares 105,943 $21.18 Direct F1
transaction ZYME Restricted Stock Unit Award $0 +17,657 $0.000000 17,657 10 Nov 2021 Common Shares 17,657 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 The restricted stock units vest in three equal annual installments beginning on November 10, 2022.